Dhampur Bio signs exclusive mycoprotein licensing deal with Planetary SA
- Dhampur Bio signs exclusive mycoprotein production license with Planetary SA
- Deal includes 10% royalty on after-tax revenue paid quarterly
- Joint venture formed for commercialization and offtake in India
- Sugar and molasses to serve as feedstock for new product line

*this image is generated using AI for illustrative purposes only.
Dhampur Bio Organics Limited executed a Technology Licensing Agreement with Planetary SA, Switzerland, on October 19, 2026. The deal grants exclusive rights for mycoprotein production in India, marking a strategic forward integration for the sugar and molasses producer.
This agreement follows a non-binding term sheet signed in January 2026. It establishes a synergetic license-based collaboration where Dhampur acts as the manufacturer and supplier, while Planetary serves as the technology provider and off-taker of the final products.
Agreement Structure and Joint Venture
The arrangement involves three key components designed to secure market entry and operational control:
- Construction and operation of mycoprotein production infrastructure by Dhampur.
- Execution of a commercialization and offtake agreement.
- Formation of a joint venture company between both parties to undertake commercialization and offtake in India.
Planetary SA is responsible for providing licensed intellectual property, engineering support, launch assistance, installation, commissioning, and initial training. Dhampur is obligated to use the licensed IP only at the approved facility and comply with strict confidentiality and audit standards.
Financial Terms and Royalties
The financial structure relies on a royalty model tied to performance, ensuring alignment between technology provision and sales success.
| Component | Details |
|---|---|
| Licensing Fee/Royalty | 10% of after-tax revenue, paid quarterly |
| One-Time Launch Fee | Charged on an open-book basis for engineering, launch, installation, commissioning, process training, and handover support |
| IT Setup Fee | One-time payment for Data Platform configuration |
| Agreement Term | Initial term of 10 years, renewable in successive 5-year terms |
Strategic Rationale
The company identified synergy between its existing business operations and the new technology. Sugar and molasses will serve as feedstock for mycoprotein production, representing a forward integration step. This move is expected to introduce a new revenue stream and enhance overall profitability by leveraging existing raw material supply chains.
What the Numbers Show
The disclosure highlights a dependency on external technology for a new product line while retaining manufacturing control. The 10% royalty on after-tax revenue creates a direct link between Dhampur’s profitability and Planetary’s compensation. Additionally, the requirement to pay a one-time launch fee on an "open-book basis" suggests that initial capital expenditure and setup costs remain variable until completion, potentially impacting short-term cash flows before steady-state royalties begin.
Source:
Historical Stock Returns for Dhampur Bio Organics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -6.47% | -6.86% | +16.07% | +15.25% | +67.55% | -21.70% |
How will the open-book launch fee structure impact Dhampur's short-term capital expenditure guidance and free cash flow projections for FY2027?
What is the projected timeline for the joint venture to achieve commercial-scale production, and how does this align with India's evolving regulatory framework for novel food proteins?
How does the 10% royalty on after-tax revenue affect Dhampur's EBITDA margins compared to its traditional sugar and ethanol segments?


































